Sergey A. Parts

Sergey A. Parts

Auto-generated profile, based on publicly available information

Sergey A. Parts

Moscow City Hospital named after S.S. Yudin

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2023 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
SPSergey A. Parts
Sergey A. Parts
IRIgor V. Reshetov
Igor V. Reshetov
EKEvgeniya S. Kuzmina
Evgeniya S. Kuzmina
VGVsevolod N. Galkin
Vsevolod N. Galkin
The main objective of the oncology patient routing system in the region is to ensure the accessibility and quality of outpatient oncology care. According to the regulatory documents of the Ministry of Health of Russia, the key role in the routing system is assigned to outpatient cancer care centers. We analyzed the regulatory requirements for the operation of the centers and proposed algorithms for their integration in the regions. Based on the developed algorithms, routing modeling and a rank assessment of the models were performed with a subsequent risk assessment and rationale for organizational measures to mitigate the risks.

6 May 2024 in Voprosy onkologii
Verified
Journal Article
Open access
СПСергей Адольфович Партс
Сергей Адольфович Партс
ИРИгорь Владимирович Решетов
Игорь Владимирович Решетов
ЕКЕвгения Сергеевна Кузьмина
Евгения Сергеевна Кузьмина
ВГВсеволод Николаевич Галкин
Всеволод Николаевич Галкин
Важным звеном системы маршрутизации пациентов с опухолевой патологией в Российской Федерации являются центры амбулаторной онкологической помощи. В качестве одной из основных функций центров определено проведение мультидисциплинарных консилиумов. В условиях значительной нагрузки на амбулаторное звено онкологической службы актуальной задачей является обеспечение высокопоточной работы консилиумов без потери качества принимаемых решений. Нами изучен перечень вопросов, решаемых на онкологических консилиумах, и проведен SWOT-анализ их работы при условии высокой нагрузки. В ходе анализа выявлены зоны неэффективной организации, проведена их ранговая оценка и предложены мероприятия по снижению выявленных рисков.

18 December 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
OSOlesia A. Stativko
Olesia A. Stativko
IPIlya A. Pokataev
Ilya A. Pokataev
SKSergey A. Kravtsov
Sergey A. Kravtsov
LZLiudmila Zhukova
Liudmila Zhukova
DSDaniil L. Stroyakovskiy
Daniil L. Stroyakovskiy
КАКравцов Сергей Анатольевич
Кравцов Сергей Анатольевич
Background. The approved regimen of induction chemotherapy with docetaxel + cisplatin + 5-fluorouracil has high risk of unacceptable toxicity for many patients with advanced head and neck cancer (HNSCC). Toxicity can also compromise the delivery of the following chemoradiation. In order to improve the results of these pts treatment we conducted a prospective multicenter non-randomized phase II study of induction immunochemotherapy followed by (chemo)radiation and here we report first results of objective response rate (ORR), the safety profile of induction therapy and risk of further radiation therapy omission (NCT05551767). Materials and methods. The inclusion criteria were: unresectable stage III–IVA cancer of larynx, oropharynx, hypopharynx, PD-L1-positive (CPS≥1) squamous cell cancer, ECOG 0-2. Included pts received 3 cycles of pembrolizumab 200 mg d1+ cisplatin 100 mg/m2 d1 + 5-fluorouracil 1000 mg/m2/day 1-4 d followed by (chemo-) radiation. Results. Since January 2022 a total of 120 pts were included. Median age was 60 (35–75), the majority were male (105; 87.5%). Objective responses were assessed in 116 of 120 pts. ORR on induction phase was 62.9% (n=73), including 16.4% (n=19) of complete responses. Median change of target lesions was -55% (from -100% to 65%). To date, only 7 pts did not start (chemo)radiation in time due to disease progression (4 pts) or refuse of consent (3 pts). Among 95 pts who completed radiation therapy 94.7% received radiation dose ≥66Gy. The incidence of grade 3-4 adverse events was 30,8%, in 6 (5%) pts it required hospitalization. No grade 5 adverse events were observed. The most common toxicity was hematological with neutropenia grade 3-4 in 28 (23.3%) pts. There was mild immune-related toxicity: 2 (1.7%) pts had skin rash and 1 (0.8%) – hypothyroidism. The use of high dose of cisplatin resulted in a trend to decline glomerular filtration rate (median decrease was 10.5% from baseline) although none of pts required hemodialysis. Conclusion. Induction therapy with pembrolizumab plus cisplatin and 5-fluorouracil provided meaningful ORR and acceptable safety profile in locally advanced HNSCC. It almost did not influence the following radiation therapy omission rate. Further follow-up is needed to assess long-term efficacy.

19 June 2023 in City Healthcare
Verified
Journal Article
Open access
PDF file
АСАнна Борисовна Семенова
Анна Борисовна Семенова
MBMariya M. Byakhova
Mariya M. Byakhova
ВГВсеволод Николаевич Галкин
Всеволод Николаевич Галкин
СПСергей Адольфович Партс
Сергей Адольфович Партс
MMMaria V. Makarova
Maria V. Makarova
АКАнастасия Александровна Криницына
Анастасия Александровна Криницына
Russia and other countries report an increase in the incidence of malignant neoplasms, and approximately 10 % of all oncological cases have hereditary background. Molecular genetic testing in patients with diagnosed malignant neoplasms and a suspected hereditary factor will help to select effective modern methods of treatment and prevention of the development of neoplasms of other localizations. According to the study, 12,6 % of patients had hereditary cancer syndrome, which allowed to administer molecular genetic tests to patients’ relatives. Consequently, it becomes possible to detect hereditary cancer risk factors, improve the efficiency of clinical examination, elaborate and implement programs for prevention and early detection of the disease.

11 November 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
EKEvgeniya S. Kuzmina
Evgeniya S. Kuzmina
MFMikhail Fedyanin
Mikhail Fedyanin
MLMarina A. Lyadova
Marina A. Lyadova
DFDenis Fedorinov
Denis Fedorinov
MPMaxim A. Polyanskiy
Maxim A. Polyanskiy
ПАПолянский Максим Александрович
Полянский Максим Александрович
Aim. To compare the efficacy of regorafenib and the combination of chemotherapy (CT) with anti-EGFR (cetuximab/panitumumab) in the third-line treatment of metastatic colorectal cancer (mCRC). Materials and methods. A retrospective analysis of a prospective database of patients with mCRC from two clinics in the Russian Federation was conducted. Overall survival was considered the primary efficacy criterion. Additional criteria were progression-free survival (PFS), objective effect (OE), and incidence of toxicity. No statistical hypothesis was assumed. Statistical analysis was performed using SPSS (IBM SPPS Statistics v. 20). Results. The database identified 51 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received more than two lines of antitumor drug therapy from 2010 to 2021, one of which included anti-EGFR antibodies in the third and subsequent lines of treatment. Thirty patients who received regorafenib in the third line and 21 patients who received CT in combination with anti-EGFR in the third line were selected, of which 7 patients had a history of anti-EGFR use, and 14 patients received anti-EGFR for the first time. The median overall survival from the third line initiation date in the CT group in combination with anti-EGFR was numerically higher (21 months, CI 9.0–32.9 months) than in the regorafenib group (10 months, CI 2.4–17.5 months); p=0.1 by log-rank test (Mantel–Cox test); p=0.2 by Breslow–Wilcoxon test; p=0.3 (Tarone–Ware test). PFS was also higher in the anti-EGFR CT group (6 months, CI 3.8–8.2 months) than in the regorafenib group (3 months, CI 1.2–4.7 months); p=0.05 according to Breslow–Wilcoxon test. OE of third-line therapy was reported in 57.1% (n=12) of patients in the CT with anti-EGFR group and significantly less often in the regorafenib group – 10.3% (n=3) of patients (p=0.001). The toxicity of drug therapy of all grades in the regorafenib group was reported in 86.2% (n=25) of patients, while in the CT anti-EGFR group, it was significantly less common – in 52.4% (n=11) of patients (p=0.01). Conclusion. Compared with regorafenib, combining CT with anti-EGFR agents in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes is associated with better PFS and the frequency of OE with significantly less toxicity.

30 August 2024 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
SPSergey A. Parts
Sergey A. Parts
YGYana V. Gridneva
Yana V. Gridneva
MVMaria I. Volkova
Maria I. Volkova
AOAlbert V. Oskarev
Albert V. Oskarev
OSOgulshat R. Sinitsyna
Ogulshat R. Sinitsyna
SGSaida M. Gadzhieva
Saida M. Gadzhieva
Background. The clinical course of non-muscle-invasive bladder cancer is characterized by a tendency to develop local recurrences and the ability to tumor progression. The most effective method of preventing disease progression after transurethral resection of the bladder in patients of intermediate and high-risk groups is intravesical therapy with BCG antitumor vaccine containing attenuated Mycobacterium tuberculosis. Taking into account the increasing incidence non-muscle-invasive bladder cancer in Moscow, the organization of adequate use of BCG vaccine in clinical practice requires the involvement of significant organizational and human resources. Aim. To develop and validate an organizational model for the delivery of BCG therapy for non-muscle-invasive bladder cancer at an outpatient cancer care center using hospital-substitution technologies. Materials and methods. In the period from June 2023 to May 2024, BCG therapy has been performed in Oncology Center №1 of Yudin Moscow City Hospital in 180 patients with verified non-muscle-invasive bladder cancer of intermediate and high-risk groups. Results. The study revealed a trend towards an increase in the absolute number of early bladder cancer in Moscow in the period 2018–2023. According to clinical guidelines, treatment of patients with non-muscle-invasive bladder cancer includes determination of the risk of recurrence and tumor progression with subsequent formation of indications for intravesical BCG therapy. The regimen of administration depending on the risk of recurrence includes 18–42 instillations for 12–36 months after transurethral resection of the bladder with follow-up examinations every three months. The procedure of intravesical BCG therapy takes 1–2 hours and does not require hospitalization. An organizational model of treatment an outpatient cancer care center based on various forms of hospital-substitution technologies is presented. Conclusion. Intravesical BCG therapy is a highly demanded method for the treatment of non-muscle-invasive bladder cancer. This method can be widely used in outpatient settings through the use of hospital-substitution technologies.